Background
==========

In 2018, the new incidence of renal cell carcinoma (RCC) ranked sixth among all kinds of tumors, and the death rate ranked eighth \[[@b1-medscimonit-25-3700]\]. It is estimated that 14 000 people died of RCC in 2012. The incidence of RCC varies geographically \[[@b2-medscimonit-25-3700]\]. For example, the Czech Republic had the highest incidence in the world. The incidence in Nordic and Eastern Europe, North America, and Australia increased, but was relatively lower in Africa and Southeast Asia \[[@b3-medscimonit-25-3700]\]. The reasons for the higher incidence in developed countries are not yet clear. Genomics, occupation, environmental exposures, and smoking are implicated \[[@b2-medscimonit-25-3700]\].

RCC is divided into many different histological types. The clear cell type accounts for 70.90% of all RCC, followed by papilla (10--15%) and chromophobe RCCs (3--5%). Clear cell RCC is worse than papillary or chromophobe RCC, and is more likely to occur in late stage or metastasis \[[@b4-medscimonit-25-3700],[@b5-medscimonit-25-3700]\]. In 90% of clear cell RCCs, tumors exhibit alteration the von Hippel-Lindau tumor suppressor (VHL) gene through genetic or epigenetic mechanisms \[[@b6-medscimonit-25-3700],[@b7-medscimonit-25-3700]\]. The inactivation of VHL leads to a lower ubiquitination of hypoxia induced factor (HIF-α) and subsequently induces the expression of vascular endothelial growth factor (VEGF), both strictly linked to tumor angiogenesis \[[@b8-medscimonit-25-3700]\]. VHL and VEGF has been validated as predictive and prognostic markers in RCC \[[@b9-medscimonit-25-3700]\]. Further insights into the molecular biology of RCC could help find novel molecular biomarkers and potential targets for early diagnosis and precise treatment.

Elevated serum ferritin has been proved to play an important role in iron transport, angiogenesis, inflammation, immunity, signal transduction, and cancer in many human diseases \[[@b10-medscimonit-25-3700]\]. Ferritin consists of 24 polypeptide subunits of heavy chain (FTH1) and light chain (FTL) \[[@b11-medscimonit-25-3700],[@b12-medscimonit-25-3700]\]. In patients with RCC, serum ferritin concentration is significantly higher than in normal controls \[[@b13-medscimonit-25-3700]\], and even associates with the presence of distant metastasis \[[@b14-medscimonit-25-3700]\]. It is suggested that serum ferritin may be a useful tumor marker for renal cell carcinoma.

Ferritin consists of the heavy and light chains, encoded by FTH1 and FTL1 genes, respectively. FTH1 is differentially and abnormally expressed in tissues from multiple malignancies, including astrocytic brain tumors \[[@b15-medscimonit-25-3700]\], prostate cancer \[[@b16-medscimonit-25-3700]\], and breast cancer \[[@b17-medscimonit-25-3700]\]. FTH1 has recently been considered a good prognostic protein for triple-negative breast cancer (TNBC) patients \[[@b17-medscimonit-25-3700]\]. However, the expression of FTH1 is unclear in RCC.

The purpose of this study was to analyze the difference between FTH1 gene expression in RCC and normal renal tissues, and to explore the relationship between FTH1 gene expression and clinical characteristics and prognosis of RCC.

Material and Methods
====================

The Cancer Genome Atlas (TCGA) database analysis
------------------------------------------------

TCGA is a huge repository of high-throughput data of DNA, RNA, and protein in a variety of human cancers, which is helpful in comprehensive analysis of the expression of these components in various cancer types \[[@b18-medscimonit-25-3700]\]. The data of FTH1 mRNA expression in primary RCC and normal control samples, as well as clinicopathological characteristics of patients, were obtained from TCGA database (*<https://xena.ucsc.edu/>*). SPSS 22.0 software was used to analyze the differential expression of FTH1 in RCC and the relationship between FTH1 level and clinicopathological parameters and Cox multivariate survival. The survival curve was analyzed using GraphPad software.

### Oncomine database analysis

Oncomine databases are online collections of microarrays from various sources, often associated with cancer, and contain many "multiple arrays" (collections of microarrays analyzed in a single study) \[[@b19-medscimonit-25-3700]\]. The relative expression level of "FTH1" gene was searched in the "kidney cancer" dataset in the analysis type of "cancer *vs.* normal analysis".

Selection of studies and microarrays in GEO datasets
----------------------------------------------------

The mRNA expression of FTH1 in RCC was investigated in GEO database, with search terms as follow: 1) "renal cancer", 2) "kidney OR renal AND cancer OR carcinoma OR tumor OR neoplasm\* OR malignant\*". Microarray was used to examine the expression of FTH1 in RCC tissues and normal tissues, including meta-analysis. The criteria of inclusion were: 1) have more than 6 samples, and 2) sampled FTH1 from human tissues.

Real-time reverse transcription polymerase chain reaction
---------------------------------------------------------

The transcriptional level of FTH1 was confirmed in normal renal epithelial cell 293 and renal cancer cell 786-0, which were stored in our lab. cDNA of primary renal cell carcinoma tissues and matched adjacent tissues were obtained from Shanghai Outdo Biotech Co. (Shanghai, China; Cat no: MecDNA-HKidE030CS01). The relative expression levels of FTH1 were detected using the Power SYBR Green PCR Master Mix (Foster City, CA, USA, Applied Biosystem) in a QuantStudio 5 Real-Time PCR System (Foster City, CA, USA, Applied Biosystem). After the reactions were completed, the comparative threshold cycle (Ct) method was used to calculate the relative gene expression. The sequences of primers used were as follows:

1.  FTH11-Forward, 5′-AAGCTGCAGAACCAACGAGG-3′,

2.  FTH1-Reverse, 5′-AGTCACACAAATGGGGGTCATT-3′;

3.  GAPDH1-Forward, 5′-AAGCTCACTGGCATGGCCTT-3′,

4.  GAPDH-Reverse, 5′-CTCTCTTCCTCTTGTGCTCTTG-3′.

The Human Protein Atlas (HPA)
-----------------------------

HPA is a pathology tool that provides a large number of protein expression profiles of human proteins. Clinical tumor tissue samples come from a clinical biobank, including a large number of retrospectively collected patient cohorts and long-term follow-up for research. Here, we used this tool to compare the expression of RCC tissues and normal tissues at the protein level.

cBioPortal for ClueGo
---------------------

The co-expression genes of FTH1 in KIRC (\|Pearson's r\|≥0.4 and \|Spearman's r\|≥0.4) were identified by cBioPortal network tools. Then, genes were loaded into ClueGo in CytoCop3.3.1 to analyze GO and KEGG pathways. Only a path with a p value of 0.05 was included. In addition, co-expressed genes (\|Pearson's r\|≥0.5 and \|Spearman's r\|≥0.5) were selected and STING was used for PPI network analysis.

Statistical analysis
--------------------

All statistical analyses were performed using SPSS 22.0 software. The correlation between FTH1 gene expression and clinical pathological parameters of RCC patients was evaluated by independent-samples *t* test. The differences in TNM stages were tested using analysis of variance (ANOVA). Cox multivariate survival analysis was performed to predict unfavorable prognosis. The diagnostic value of FTH1 in RCC was evaluated by receiver operating characteristic (ROC) curve. Kaplan-Meier curves and logarithmic rank test were used to analyze the survival of RCC patients. STATA 12 software was used for meta-analysis. p≤0.05 was considered statistically significant.

Results
=======

Association between FTH1 expression and clinicopathological parameters, diagnosis and prognosis of RCC patients
---------------------------------------------------------------------------------------------------------------

According to TCGA data, over-expression of FTH1 was detected in 890 RCC tissues (15.2904±0.63157) compared to 129 normal kidney tissues (14.4502±0.51523, p\<0.001; [Figure 1A](#f1-medscimonit-25-3700){ref-type="fig"}). This was further confirmed in cell lines and tissues by real-time RT-PCR. In contrast with normal renal epithelial cell line 293, the mRNA level of FTH1 was elevated in renal cell carcinoma cell line 786-0 ([Figure 1B](#f1-medscimonit-25-3700){ref-type="fig"}). We also observed a relatively higher expression of FTH1 in 10 out of 14 primary RCCs than in matched adjacent samples ([Figure 1C](#f1-medscimonit-25-3700){ref-type="fig"}). There was a significant difference between the expression of FTH1 and age, T stage, M stage, and lymph node metastasis ([Table 1](#t1-medscimonit-25-3700){ref-type="table"}). Patients age \<60 years showed a lower FTH1 expression compared with those age ≥60 years. The expression of FTH1 was also remarkably different in different T and M stages. Patients with lymph node metastasis also had higher FTH1 expression and metastasis.

Kaplan-Meier survival analysis showed that FTH1 expression level, age, lymphatic metastasis, stage, T stage, and M stage were important parameters affecting survival time of RCC patients ([Table 2](#t2-medscimonit-25-3700){ref-type="table"}). In addition, Cox multivariate survival analysis was performed, including 6 significant statistical parameters, and demonstrated that age, stage, and M stage were predictors of adverse prognosis in patients with RCC ([Table 3](#t3-medscimonit-25-3700){ref-type="table"}).

The P value of ROC curve was \<0.001, revealing that the expression of FTH1 is associated with diagnosis of RCC (AUC=0.849, 95% CI: 0.818--0.880, p\<0.001; [Figure 1D](#f1-medscimonit-25-3700){ref-type="fig"}). The Kaplan-Meier curve showed that of RCC patients with high FTH1 expression had worse outcomes (p=0.0014; [Figure 1E](#f1-medscimonit-25-3700){ref-type="fig"}).

Association between FTH1 expression and clinicopathological parameters, diagnosis, and prognosis of KIRC, KICH, and KIRP patients
---------------------------------------------------------------------------------------------------------------------------------

We extracted 533 cases of KIRC, 66 cases of KICH, and 291 cases of KIRP to analyze the FTH1 expression in subtypes of RCC. In these 3 types of RCC, FTH1 expression was significantly higher than in the 129 normal controls ([Figure 2A--2C](#f2-medscimonit-25-3700){ref-type="fig"}). To further confirm this finding, we used Oncomine database to analyze the FTH1 expression in 3 types of RCC. [Figure 2D--2F](#f2-medscimonit-25-3700){ref-type="fig"} shows that FTH1 is overexpressed in KIRC, KICH, and KIRP, but the difference is significant only in KIRC and KIRP.

The expression of FTH1 was also remarkably different in different T stages in KIRC patients. These patients with lymph node or distant metastasis had higher FTH1 expression ([Table 4](#t4-medscimonit-25-3700){ref-type="table"}), but no significant difference was found between the expression of FTH1 and any clinical characteristics in KICH patients ([Table 5](#t5-medscimonit-25-3700){ref-type="table"}). KIRP patients age \<60 years showed lower FTH1 expression compared with those age ≥60 years. The expression of FTH1 was also remarkably different in different T stages. Patients with lymph node or distant metastasis also had higher FTH1 expression ([Table 6](#t6-medscimonit-25-3700){ref-type="table"}).

The ROC curve was used to assess the diagnostic performance of FTH1 expression in KIRC, KICH, and KIRP ([Figure 2G--2I](#f2-medscimonit-25-3700){ref-type="fig"}); the AUC was 0.880 (95% CI: 0.841--0.919, p\<0.001), 0.868 (95% CI: 0.786--0.950, p\<0.001), and 0.868 (95% CI: 0.786--0.950, p\<0.001), respectively. This indicates that the transcription of FTH1 could be used as a diagnostic biomarker for all 3 subtypes of RCC.

The Kaplan-Meier curves shown in [Figure 2J--2L](#f2-medscimonit-25-3700){ref-type="fig"} revealed no predictive value in KIRC, KIRP, or KICH patients.

Meta-analysis of FTH1 expression in RCC
---------------------------------------

To evaluate the consistency of FTH1 abnormal expression in RCC, 18 microarray studies involving 738 RCC tissues and 469 normal tissues in GEO database were included for meta-analysis, in which we combined the effective data (GEO and TCGA) and used the random-effects model to obtain the pooled Standard Mean Difference (SMD) as 0.64 (95% CI: 0.53--0.75, p\<0.001; [Figure 3](#f3-medscimonit-25-3700){ref-type="fig"}), and the p value of the heterogeneity test was less than 0.001 (I^2^=87.0%). Sensitivity analysis showed that no single study led to significant bias in overall merger results ([Figure 4](#f4-medscimonit-25-3700){ref-type="fig"}). In addition, no significant publication bias was found in the study (Begg's test: p=0.054; [Figure 5](#f5-medscimonit-25-3700){ref-type="fig"}). Relevant information was extracted from each study, such as ID number, first author, public year, country, sample type, platform, number of cancer cases, mean (M) and standard deviation (SD) of FTH1 expression in the cancer group, and normal tissue N, M, and SD of FTH1 expression in the normal group ([Table 7](#t7-medscimonit-25-3700){ref-type="table"}).

FTH1 protein expression in RCC tissues from HPA
-----------------------------------------------

Using the HPA database, we compared 3 normal samples and 3 RCC samples, which showed an elevation of FTH1 protein in RCC ([Figure 6](#f6-medscimonit-25-3700){ref-type="fig"}).

The GO, KEGG network, and PPI network with co-expressed genes of FTH1
---------------------------------------------------------------------

Among these co-expressed genes, 278 genes were selected for GO and pathway analyses ([Figures 7](#f7-medscimonit-25-3700){ref-type="fig"}[](#f8-medscimonit-25-3700){ref-type="fig"}--[9](#f9-medscimonit-25-3700){ref-type="fig"}). These genes are abundantly expressed in positive regulation of the Wnt signal transduction pathway, response to oxygen level, binding of ribosome subunits, and RNA polymerase. In addition, KEGG pathway analysis showed that the expression of FTH1 co-expression gene in hepatocellular carcinoma, proteasome, and ribosome was significantly higher than in the control group ([Figure 10](#f10-medscimonit-25-3700){ref-type="fig"}). The most important GO items (BP, CC, and MF) are listed in [Table 8](#t8-medscimonit-25-3700){ref-type="table"} and the PPI network is shown in [Figure 11](#f11-medscimonit-25-3700){ref-type="fig"}.

Discussion
==========

To date, no diagnostic modality for early detection of RCC has been established, other than incidental radiologic discovery. Some promising studies have identified several potential biomarkers in sera and urine. For example, tumor necrosis factor receptor-related factor-1, heat shock protein 27, carbonic anhydrase IX, and ferritin in RCC patients were significantly higher than those in control serum \[[@b20-medscimonit-25-3700]--[@b24-medscimonit-25-3700]\], while nuclear matrix protein-22, kidney injury molecule-1, matrix metalloproteinases, aquaporin-1, and perilipin 2 are elevated in urine \[[@b25-medscimonit-25-3700]--[@b28-medscimonit-25-3700]\]. However, none of these have been used in clinic practice for RCC diagnosis. In this study, we used bioinformatic approaches to reveal the relationship between FTH1 and the clinical characteristics of RCC patients. The RNA-seq data from TCGA showed that FTH1 is overexpressed in RCC tissues. FTH1 transcription level was significantly correlated with pathological T stage, lymph node, and distant metastasis of KIRC, and was significantly correlated with pathological T stage and lymph node metastasis of KIRP, suggesting that FTH1 may be a potential biomarker for clinical stages of these 2 RCC subtypes. Meta-analysis results showed that FTH1 was overexpressed in RCC according to 18 microarray datasets from GEO. However, heterogeneity was moderately high and publication bias was obvious, probably due to small sample size and datasets of varying quality.

Currently available biomarkers seem to be most useful as diagnostic tools, prognostic indicators, and follow-up in patients with renal cancer \[[@b29-medscimonit-25-3700]\]. Steven et al. reported that the positive expression of receptor activator of NF-κB had both worse cancer-specific survival and recurrence-free survival in RCC patients \[[@b30-medscimonit-25-3700]\]. Increased expression of long noncoding RNA GIHCG is positively correlated with advanced TNM stages, Fuhrman grades, and poor prognosis \[[@b31-medscimonit-25-3700]\]. In a meta-analysis of 2013 patients, including 22 studies, positive expression of P53 was associated with poor prognosis and advanced clinicopathological features in RCC patients \[[@b32-medscimonit-25-3700]\]. The nuclear translocation of CXCR4 plays an important role in RCC metastasis and is associated with poor prognosis \[[@b33-medscimonit-25-3700]\]. Here, we found that RCC patients with higher FTH1 expression in primary RCC were associated with a shorter survival time. Besides, RCC patients with lymph node and distant metastasis had higher FTH1 expression metastasis, which indirectly suggests a poorer prognosis. These finding suggest that the high expression of FTH1 could be used as a predictor to indicate the poor prognosis of RCC patients.

Dysregulation of iron homeostasis has been linked to numerous diseases, such as cancer and neurodegenerative diseases \[[@b34-medscimonit-25-3700],[@b35-medscimonit-25-3700]\]. Cellular iron regulation includes iron uptake, storage, and export. Iron-regulated proteins, such as transferrin receptors in glioblastoma and ferritin in serum, were upregulated, thereby increasing iron uptake \[[@b36-medscimonit-25-3700],[@b37-medscimonit-25-3700]\]. Ferritin plays an important role in the storage and release of iron in cells. Ferritin complexes capture intracellular ferrous ions (Fe^2^) and convert them into iron ions (Fe^3^) by the activity of ferrous oxidase \[[@b38-medscimonit-25-3700]\]. It consists of 24 subunits of heavy and light ferritin chains (FTH1 and FTL1). In this study, we found that there was no significant correlation between the expression of FTL1 and RCC (data not shown), suggesting that FTH1 might play an important role in the tumorigenesis of RCC. In addition, approaches targeting cellular iron and iron signaling to inhibit tumor growth have been developed and applied in cancer therapy. The application of iron chelators can suppress tumor growth and induce apoptosis, which suggests iron chelators as potential anti-cancer drugs \[[@b39-medscimonit-25-3700],[@b40-medscimonit-25-3700]\]. FTH1 controls HIF-induced hypoxia by activating asparagine hydroxylase and affects the expression of HIF-1 target gene \[[@b38-medscimonit-25-3700]\]. Based on our results of GO analyses, the top enriched functional term of FTH1 genes were regulation of Wnt signaling pathway and response to cellular hypoxia. Overexpressing FTH1 in acute myeloid leukemia (AML) stem cells significantly induced the expression of genes involved in immune and inflammatory response, including NF-κB pathway, oxidative stress, and iron pathways \[[@b41-medscimonit-25-3700]\]. These findings suggest that FTH1 could be a novel therapeutic target.

The limitations of this study should be considered. The expression of FTH1 in RCC and its correlation with clinical features were analyzed and validated only in TCGA and GEO datasets. Further research is needed to improve our understanding of the functional role of FTH1 in RCC.

Conclusions
===========

In this study, we found that expression of FTH1 is elevated in RCC, which could serve as a potential diagnosis and prognosis biomarker. Our data suggest that higher mRNA levels of FTH1 might contribute to the progression of RCC, and thus could be used as a target for RCC therapy.
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![The transcriptional level of FTH1 gene is higher in renal cell carcinoma (RCC) than in normal kidney tissues. (**A**) The mRNA expression of FTH1 in 890 cases of RCC and 129 cases of normal kidney tissues based on TCGA database. (**B**) FTH1 mRNA expression was detected by RT-qPCR in renal cancer cell 786-0 and renal epithelial cell 293, normalized to GAPDH. (**C**) The mRNA expression of FTH1 in 14 primary renal cell carcinoma tissues and matched adjacent tissues. (**D**) The ROC curve for evaluating the diagnostic performance of FTH1 in 890 cases of RCC and 129 cases of normal kidney tissues. The AUC was 0.849. (**E**) The overall survival (OS) of RCC patients with high and low mRNA level of FTH1, which was divided by the median of FTH1 mRNA expression in 890 cases of RCC.](medscimonit-25-3700-g001){#f1-medscimonit-25-3700}

![The transcriptional level of FTH1 gene is higher in KIRC, KICH, and KIRP in contrast with normal kidney tissues. Higher expression of FTH1 was associated with poorer prognosis of KIRC patients. (**A--C**) Scatter plot of FTH1 gene expression in normal tissues in contrast with 3 subtypes of RCC. (**D--F**) Validation of FTH1 expression in Jone's study using ONOCMINE database. (**G--I**) ROC curve of FTH1 for patients with KIRC, KICH, and KIRP. The AUC was 0.88 (95% CI: 0.841--0.919, p\<0.001), 0.868 (95% CI: 0.786--0.950, p\<0.001), and 0.765 (95% CI: 0.697--0.834, p\<0.001). (**J--L**) The overall survival (OS) of patients with KIRC, KICH, and KIRP.](medscimonit-25-3700-g002){#f2-medscimonit-25-3700}

![Meta-analysis of FTH1 expression in renal cell carcinoma based on tumor types. A total of SMDs with 95% CI accounted for 0.64 (0.53, 0.75). RCC tissue subgroup was highly heterogeneous (I^2^=87.0%, p\<0.001).](medscimonit-25-3700-g003){#f3-medscimonit-25-3700}

![Meta-analysis of FTH1 expression in renal cell carcinoma showed no significant difference in sensitivity analysis.](medscimonit-25-3700-g004){#f4-medscimonit-25-3700}

![Meta-analysis of FTH1 expression in renal cell carcinoma using Begg funnel map. Symmetric Begg funnel map indicated publication bias (p=0.054).](medscimonit-25-3700-g005){#f5-medscimonit-25-3700}

![Validation of the protein expression of FTH1 in normal kidney control samples (**A--C**) and RCC samples using the HPA database (**D--F**).](medscimonit-25-3700-g006){#f6-medscimonit-25-3700}

![The GO map of BP corresponding to the target gene of FTH1.](medscimonit-25-3700-g007){#f7-medscimonit-25-3700}

![The GO map corresponds to the target gene CC of FTH1.](medscimonit-25-3700-g008){#f8-medscimonit-25-3700}

![The GO map of MF corresponding to the target gene of FTH1.](medscimonit-25-3700-g009){#f9-medscimonit-25-3700}

![KEGG pathway analysis of co-expression genes of FTH1 target genes.](medscimonit-25-3700-g010){#f10-medscimonit-25-3700}

![The PPI network of FTH1 target genes.](medscimonit-25-3700-g011){#f11-medscimonit-25-3700}

###### 

Relationship between the expression of FTH1 and clinicopathological parameters in RCC.

  Clinicopathological parameters   n        Relevant expression of FTH1 (log~2~X)                                                                                   
  -------------------------------- -------- --------------------------------------- ----------------- ------------------------------------------------------------- -----------------------------------------------------------
  Age (years)                      \<60     416                                     15.2286±0.61648   −2.708[a](#tfn2-medscimonit-25-3700){ref-type="table-fn"}     0.007[\*](#tfn4-medscimonit-25-3700){ref-type="table-fn"}
  ≥60                              473      15.3431±0.64018                                                                                                         
  Gender                           Male     598                                     15.2610±0.62896   −1.933[a](#tfn2-medscimonit-25-3700){ref-type="table-fn"}     0.054
  Female                           291      15.3481±0.63356                                                                                                         
  Lymph node metastasis            Yes      224                                     15.4004±0.63564   3.083[a](#tfn2-medscimonit-25-3700){ref-type="table-fn"}      0.002[\*](#tfn4-medscimonit-25-3700){ref-type="table-fn"}
  No                               654      15.2505±0.62575                                                                                                         
  Stage                            I--II    563                                     15.2102±0.61155   −5.534[a](#tfn2-medscimonit-25-3700){ref-type="table-fn"}     0.000[\*](#tfn4-medscimonit-25-3700){ref-type="table-fn"}
  III--IV                          294      15.4558±0.62696                                                                                                         
  T                                T1--T2   614                                     15.2076±0.61946   −5.883[a](#tfn2-medscimonit-25-3700){ref-type="table-fn"}     0.000[\*](#tfn4-medscimonit-25-3700){ref-type="table-fn"}
  T3--T4                           275      15.4724±0.62058                                                                                                         
  Pathologic stage                 I        460                                     15.2132±0.61193   F=11.492[b](#tfn3-medscimonit-25-3700){ref-type="table-fn"}   0.000[\*](#tfn4-medscimonit-25-3700){ref-type="table-fn"}
  II                               103      15.1969±0.61267                                                                                                         
  III                              189      15.4041±0.62942                                                                                                         
  IV                               105      15.5490±0.61454                                                                                                         
  Pathologic T                     T1       487                                     15.2095±0.61613   F=12.300[b](#tfn3-medscimonit-25-3700){ref-type="table-fn"}   0.000[\*](#tfn4-medscimonit-25-3700){ref-type="table-fn"}
  T2                               127      15.2004±0.63447                                                                                                         
  T3                               258      15.4581±0.60455                                                                                                         
  T4                               17       15.6888±0.81950                                                                                                         
  M                                No       224                                     15.4004±0.63564   3.083[a](#tfn2-medscimonit-25-3700){ref-type="table-fn"}      0.002[\*](#tfn4-medscimonit-25-3700){ref-type="table-fn"}
  Yes                              654      15.2505±0.62575                                                                                                         

SD -- standard deviation; RCC -- renal cell carcinoma.

A Student's paired or unpaired t test was used for comparison between two group;

One-way analysis of variance (ANOVA) was performed.

p\<0.05 was considered statistically significant.

###### 

Kaplan-Meier univariate survival analysis of FTH1 and other clinicopathological parameters in RCC patients.

  Clinicopathological parameters   Mean survival time (months)   95% CI             P value
  -------------------------------- ----------------------------- ------------------ -----------------------------------------------------------
  FTH1 expression                                                                   
   Low                             135.153                       123.535--146.772   0.001[\*](#tfn5-medscimonit-25-3700){ref-type="table-fn"}
   High                            97.873                        89.98--105.767     
  Age (years)                                                                       
   \<60                            147.369                       137.543--157.195   0.000[\*](#tfn5-medscimonit-25-3700){ref-type="table-fn"}
   ≥60                             93.557                        85.903--101.211    
  Gender                                                                            
   Female                          103.728                       94.55--112.906     0.469
   Male                            125.38                        114.575--136.185   
  Lymph                                                                             
   No                              107.774                       101.082--114.465   0.000[\*](#tfn5-medscimonit-25-3700){ref-type="table-fn"}
   Yes                             114.567                       101.158--127.976   
  Stage                                                                             
   I--II                           123.444                       116.697--130.191   0.000[\*](#tfn5-medscimonit-25-3700){ref-type="table-fn"}
   III--IV                         85.857                        73.647--98.066     
  T                                                                                 
   T1--T2                          120.245                       113.691--126.799   0.000[\*](#tfn5-medscimonit-25-3700){ref-type="table-fn"}
   T3--T4                          87.209                        74.525--99.893     
  M                                                                                 
   No                              112.629                       106.22--119.039    0.000[\*](#tfn5-medscimonit-25-3700){ref-type="table-fn"}
   Yes                             103.131                       87.961--118.302    

p\<0.05 was considered statistically significant.

###### 

Cox multivariate analysis of FTH1 and other clinicopathological parameters in RCC patients.

  Covariates                               HR      95% CI for HR   P value
  ---------------------------------------- ------- --------------- -----------------------------------------------------------
  FTH1 expression level (low *vs.* high)   1.129   0.858--1.486    0.386
  Age (\<60 *vs.* ≥60 years)               1.655   1.249--2.192    0.000[\*](#tfn6-medscimonit-25-3700){ref-type="table-fn"}
  Lymph (no *vs.* yes)                     1.044   0.78--1.396     0.772
  Stage (I--II *vs.* III--IV)              6.032   3.445--10.564   0.000[\*](#tfn6-medscimonit-25-3700){ref-type="table-fn"}
  T (T1--2 *vs.* T3--4)                    0.661   0.394--1.109    0.117
  M (no *vs.* yes)                         1.615   1.219--2.138    0.001[\*](#tfn6-medscimonit-25-3700){ref-type="table-fn"}

p\<0.05 was considered statistically significant.

###### 

Relationship between the expression of FTH1 and clinicopathological parameters in KIRC.

  Clinicopathological parameters   n        Relevant expression of FTH1 (log~2~X)                                                                                  
  -------------------------------- -------- --------------------------------------- ----------------- ------------------------------------------------------------ ------------------------------------------------------------
  Age (years)                      \<60     245                                     15.2660±0.51809   −1.534[a](#tfn8-medscimonit-25-3700){ref-type="table-fn"}    0.126
  ≥60                              288      15.3392±0.57304                                                                                                        
  Gender                           Male     345                                     15.2739±0.56296   −1.804[a](#tfn8-medscimonit-25-3700){ref-type="table-fn"}    0.072
  Female                           188      15.3635±0.51938                                                                                                        
  Lymph node metastasis            Yes      134                                     15.4146±0.61153   2.443[a](#tfn8-medscimonit-25-3700){ref-type="table-fn"}     0.015[\*](#tfn10-medscimonit-25-3700){ref-type="table-fn"}
  No                               392      15.2159±0.78573                                                                                                        
  Stage                            I--II    324                                     15.2195±0.53435   −4.580[a](#tfn8-medscimonit-25-3700){ref-type="table-fn"}    0.000[\*](#tfn10-medscimonit-25-3700){ref-type="table-fn"}
  III--IV                          207      15.4396±0.54855                                                                                                        
  T                                T1--T2   342                                     15.2319±0.53832   −4.209[a](#tfn8-medscimonit-25-3700){ref-type="table-fn"}    0.000[\*](#tfn10-medscimonit-25-3700){ref-type="table-fn"}
  T3--T4                           191      15.4375±0.54507                                                                                                        
  Pathologic stage                 I        267                                     15.2250±0.52511   F=8.503[b](#tfn9-medscimonit-25-3700){ref-type="table-fn"}   0.000[\*](#tfn10-medscimonit-25-3700){ref-type="table-fn"}
  II                               57       15.1938±0.57990                                                                                                        
  III                              123      15.3756±0.53859                                                                                                        
  IV                               84       15.5332±0.55273                                                                                                        
  Pathologic T                     T1       273                                     15.2271±0.52558   F=6.478[b](#tfn9-medscimonit-25-3700){ref-type="table-fn"}   0.000[\*](#tfn10-medscimonit-25-3700){ref-type="table-fn"}
  T2                               69       15.2506±0.58975                                                                                                        
  T3                               180      15.4251±0.53334                                                                                                        
  T4                               11       15.6394±1.71110                                                                                                        
  M                                No       422                                     15.2636±0.53297   −3.429[a](#tfn8-medscimonit-25-3700){ref-type="table-fn"}    0.001[\*](#tfn10-medscimonit-25-3700){ref-type="table-fn"}
  Yes                              109      15.4641±0.58600                                                                                                        

SD -- standard deviation; RCC -- renal cell carcinoma.

A Student's paired or unpaired t test was used for comparison between two group;

One-way analysis of variance (ANOVA) was performed.

p\<0.05 was considered statistically significant.

###### 

Relationship between the expression of FTH1 and clinicopathological parameters in KICH.

  Clinicopathological parameters   n        Mean ±SD          t                 p value                                                       
  -------------------------------- -------- ----------------- ----------------- ------------------------------------------------------------- -------
  Age (years)                      \<60     47                15.2060±0.50464   −0.049[a](#tfn12-medscimonit-25-3700){ref-type="table-fn"}    0.961
  ≥60                              19       15.2130±0.50670                                                                                   
  Gender                           Male     39                15.2154±0.52903   0.014[a](#tfn12-medscimonit-25-3700){ref-type="table-fn"}     0.888
  Female                           27       15.1973±0.48618                                                                                   
  Lymph node metastasis            Yes      35                15.1640±0.54639   0.744[a](#tfn12-medscimonit-25-3700){ref-type="table-fn"}     0.459
  No                               31       15.2577±0.54639                                                                                   
  Stage                            I--II    46                15.1614±0.49987   −1.292[a](#tfn12-medscimonit-25-3700){ref-type="table-fn"}    0.205
  III--IV                          19       15.3432±0.52252                                                                                   
  T                                T1--T2   46                15.1428±0.49759   −1.581[a](#tfn12-medscimonit-25-3700){ref-type="table-fn"}    0.123
  T3--T4                           20       15.3581±0.51290                                                                                   
  Pathologic stage                 I        21                15.2598±0.11110   F=2.312[b](#tfn13-medscimonit-25-3700){ref-type="table-fn"}   0.085
  II                               25       15.0787±0.97330                                                                                   
  III                              13       15.1914±0.51749                                                                                   
  IV                               6        15.6593±0.40624                                                                                   
  Pathologic T                     T1       21                15.2598±0.50917   F=1.577[b](#tfn13-medscimonit-25-3700){ref-type="table-fn"}   0.209
  T2                               25       15.0444±0.47552                                                                                   
  T3                               18       15.3562±0.54161                                                                                   
  T4                               2        15.3752±0.10394                                                                                   
  M                                No       34                15.1269±0.53388   −0.555[a](#tfn12-medscimonit-25-3700){ref-type="table-fn"}    0.582
  Yes                              11       15.2290±0.51903                                                                                   

SD -- standard deviation.

A Student's paired or unpaired t test was used for comparison between two group;

One-way analysis of variance (ANOVA) was performed.

###### 

Relationship between the expression of FTH1 and clinicopathological parameters in KIRP.

  Clinicopathological parameters   n        Relevant expression of FTH1 (log~2~X)                                                                                   
  -------------------------------- -------- --------------------------------------- ----------------- ------------------------------------------------------------- ------------------------------------------------------------
  Age (years)                      \<60     121                                     15.1689±0.80649   −2.036[a](#tfn15-medscimonit-25-3700){ref-type="table-fn"}    0.043[\*](#tfn17-medscimonit-25-3700){ref-type="table-fn"}
  ≥60                              169      15.3572±0.75462                                                                                                         
  Gender                           Male     214                                     15.2485±0.73904   −1.104[a](#tfn15-medscimonit-25-3700){ref-type="table-fn"}    0.270
  Female                           76       15.3636±0.88799                                                                                                         
  Lymph node metastasis            Yes      55                                      15.5165±0.71347   −2.595[a](#tfn15-medscimonit-25-3700){ref-type="table-fn"}    0.010[\*](#tfn17-medscimonit-25-3700){ref-type="table-fn"}
  No                               231      15.2159±0.78573                                                                                                         
  Stage                            I--II    193                                     15.2106±0.74507   −2.963[a](#tfn15-medscimonit-25-3700){ref-type="table-fn"}    0.003[\*](#tfn17-medscimonit-25-3700){ref-type="table-fn"}
  III--IV                          67       15.5353±0.84850                                                                                                         
  T                                T1--T2   226                                     15.1841±0.74460   −3.763[a](#tfn15-medscimonit-25-3700){ref-type="table-fn"}    0.000[\*](#tfn17-medscimonit-25-3700){ref-type="table-fn"}
  T3--T4                           64       15.6124±0.81967                                                                                                         
  Pathologic stage                 I        172                                     15.1891±0.73811   F=3.326[b](#tfn16-medscimonit-25-3700){ref-type="table-fn"}   0.019[\*](#tfn17-medscimonit-25-3700){ref-type="table-fn"}
  II                               21       15.3870±0.79651                                                                                                         
  III                              52       15.5188±0.82226                                                                                                         
  IV                               15       15.5928±0.96255                                                                                                         
  Pathologic T                     T1       193                                     15.1791±0.73574   F=5.591[b](#tfn16-medscimonit-25-3700){ref-type="table-fn"}   0.010[\*](#tfn17-medscimonit-25-3700){ref-type="table-fn"}
  T2                               33       15.2134±0.80731                                                                                                         
  T3                               60       15.5878±0.78798                                                                                                         
  T4                               4        15.9815±1.30530                                                                                                         
  M                                No       95                                      15.1953±0.73192   −1.429[a](#tfn15-medscimonit-25-3700){ref-type="table-fn"}    0.154
  Yes                              180      15.3378±0.82060                                                                                                         

SD -- standard deviation.

A Student's paired or unpaired t test was used for comparison between two group;

One-way analysis of variance (ANOVA) was performed.

p\<0.05 was considered statistically significant.

###### 

Basic information of all included GEO datasets, array express microarray.

  ID          Author             Publish year   Country          Sample type     Cancer N   Cancer M   Cancer SD   Normal N   Normal M   Normal SD
  ----------- ------------------ -------------- ---------------- --------------- ---------- ---------- ----------- ---------- ---------- -----------
  GSE76351    Solodskikh         2015           Russia           Human tissues   12         9.1138     0.2013      12         8.9940     0.1621
  GSE66272    Wotschofsky Z      2016           Germany          Human tissues   26         0.0846     0.2991      27         −0.1014    0.3243
  GSE53757    von Roemeling CA   2014           USA              Human tissues   72         15.5405    0.5152      72         15.5225    0.3383
  GSE47032    Valletti A         2013           Italy            Human tissues   10         4.7872     0.1749      10         4.7872     0.1749
  GSE40435    Wozniak MB         2013           France           Human tissues   101        10.3477    0.4258      101        10.3630    0.3850
  GSE15641    Jones J            2009           USA              Human tissues   69         11.3989    0.5139      23         10.6087    0.3120
  GSE100666   Peng Z             2017           China            Human tissues   3          11.2542    0.0787      3          10.7352    0.1493
  GSE53000    Gerlinger M        2014           France           Human tissues   56         10.4677    0.2034      6          10.1719    0.2360
  GSE3        Boer JM            2001           Germany          Human tissues   90         5.9354     5.9755      81         5.3819     6.1432
  GSE77199    Wragg JW           2016           United Kingdom   Human tissues   12         15.9394    0.5158      12         15.8935    0.4924
  GSE72922    De Palma G         2016           Italy            Human tissues   12         10.0338    1.3682      11         9.8243     1.7273
  GSE71963    Takahashi M        2016           Japan            Human tissues   32         1.5948     0.7584      16         1.1496     0.3651
  GSE26574    Ooi A              2011           USA              Human tissues   57         11.4650    0.6121      8          10.8944    0.4178
  GSE36895    Peña-Llopis S      2012           USA              Human tissues   29         13.9418    0.3180      23         13.8316    0.1914
  GSE16449    Brannon AR         2010           USA              Human tissues   52         0.0551     0.3741      18         0.0528     0.2364
  GSE11151    Yusenko MV         2008           Netherlands      Human tissues   62         15.4108    0.4036      5          14.8845    0.3245
  GSE12606    Stickel JS         2008           Germany          Human tissues   6          10.7604    0.0924      4          10.4827    0.6190
  GSE6344     Gumz ML            2006           USA              Human tissues   10         13.6205    0.3276      10         13.3191    0.2851
  TCGA                                                           Human tissues   890        15.2904    0.6316      129        14.4502    0.5152

N -- number; M -- mean; SD -- standard deviation

###### 

Top 5 enrichment GO terms (BP, CC and MF) of the co-expression genes of FTH1.

  GO ID         GO Term                                          Ontology   Count   P Value
  ------------- ------------------------------------------------ ---------- ------- ----------
  GO: 0030177   Positive regulation of Wnt signaling pathway     BP         11      3.49E-05
  GO: 0070482   Response to oxygen levels                        BP         19      6.90E-06
  GO: 0071456   Cellular response to hypoxia                     BP         12      5.29E-05
  GO: 0071453   Cellular response to oxygen levels               BP         13      3.58E-05
  GO: 0090175   Regulation of establishment of planar polarity   BP         9       6.83E-05
  GO: 0044391   Ribosomal subunit                                CC         12      2.06E-05
  GO: 0008250   Oligosaccharyltransferase complex                CC         4       2.49E-05
  GO: 0000502   Proteasome complex                               CC         7       5.20E-05
  GO: 1905368   Peptidase complex                                CC         8       5.45E-05
  GO: 1905369   Endopeptidase complex                            CC         7       5.71E-05
  GO: 0070063   RNA polymerase binding                           MF         5       0.001002
  GO: 0015037   Peptide disulfide oxidoreductase activity        MF         3       9.22E-04

GO -- gene ontology; BP -- biological process; CC -- cellular component; MF -- molecular function.
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